Answers are grounded in this paper and cite their sources.
T-cell activation begins upon antigenic recognition by T-cell receptor and is regulated by signals generated by co-stimulating and co-inhibiting molecules. These molecules, known as immune checkpoints, are attractive therapeutic targets for the therapy of cancer and autoimmune diseases. Co-inhibiting signal pathway formed between TNF-receptor HVEM (Herpes- Virus Entry Mediator, TNFRSF14) and BTLA (B and T Lymphocyte Attenuator) limits T-cell activation. However, BTLA can serve also as activating ligand when interacts with HVEM on adjacent cell. Mutagenesis experiments have shown that the same interface is formed between HVEM and BTLA both upon cis and trans interactions thus suggesting significant conformational rearrangement in the HVEM stalk region between ectodomain and transmembrane domains upon transfer from cis to trans binding to BTLA. However, because of technical problems of the crystallization of surface receptor with long stalks, HVEM atomistic 3D-structures including stalk region are absent up to now. In this study, the approaches of structural bioinformatics were used to determine the structures of full-length proteins HVEM and BTLA and their complexes upon cis- and trans-interactions. The results obtained can be used upon developing immunoregulators for the immunotherapy of cancer and autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Urban et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: